We have located links that may give you full text access.
Clinical Trial
Comparative Study
Journal Article
F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
Endocrine Research 2003 May
UNLABELLED: Papillary carcinomas are the most common thyroid malignancies. They invade the regional lymphatics and metastasize frequently to local lymph nodes in the neck. Distant metastasis, generally to the lungs, is also common.
METHODS: The aim of this study is to evaluate the effectiveness of F18-fluorodeoxyglucose (FDG) positron emission tomography (PET) to detect metastatic lesions in patients with papillary thyroid carcinomas (PTC) after nearly total thyroidectomy and I-131 treatments who present with elevated human serum thyroglobulin (hTg) levels but negative 1-131 whole body scan (WBS). Twenty patients with PTC who underwent nearly total thyroidectomy and radioiodine treatments were included in this study.
RESULTS: All of the 20 patients had negative I-131 WBS results and elevated hTg levels (hTg > or = 2.0 microIU/mL) under thyroid-stimulating hormone (TSH) stimulation (TSH > or = 30 microIU/mL).
CONCLUSIONS: FDG-PET was perform to detect metastatic lesions. F18-fluorodeoxyglucose-PET could detect hypermetabolic lesions in 17 patients but failed to demonstrate miliary pulmonary metastases in two patients. No definite lesion was found in FDG-PET, x-ray chest computed tomography (CT) and other imaging studies of the remaining one patient This study showed that FDG-PET is a useful tool in detecting metastatic lesions in PTC with elevated hTg but negative I-131 WBS. However, miliary lung metastases may be missed in FDG-PET. In this circumstance, chest CT should be included in the follow-up protocol.
METHODS: The aim of this study is to evaluate the effectiveness of F18-fluorodeoxyglucose (FDG) positron emission tomography (PET) to detect metastatic lesions in patients with papillary thyroid carcinomas (PTC) after nearly total thyroidectomy and I-131 treatments who present with elevated human serum thyroglobulin (hTg) levels but negative 1-131 whole body scan (WBS). Twenty patients with PTC who underwent nearly total thyroidectomy and radioiodine treatments were included in this study.
RESULTS: All of the 20 patients had negative I-131 WBS results and elevated hTg levels (hTg > or = 2.0 microIU/mL) under thyroid-stimulating hormone (TSH) stimulation (TSH > or = 30 microIU/mL).
CONCLUSIONS: FDG-PET was perform to detect metastatic lesions. F18-fluorodeoxyglucose-PET could detect hypermetabolic lesions in 17 patients but failed to demonstrate miliary pulmonary metastases in two patients. No definite lesion was found in FDG-PET, x-ray chest computed tomography (CT) and other imaging studies of the remaining one patient This study showed that FDG-PET is a useful tool in detecting metastatic lesions in PTC with elevated hTg but negative I-131 WBS. However, miliary lung metastases may be missed in FDG-PET. In this circumstance, chest CT should be included in the follow-up protocol.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app